Advanced search    

Search: authors:"Andreas Clemens"

10 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Microvascular Outcomes in Patients with Type 2 Diabetes Treated with Vildagliptin vs. Sulfonylurea: A Retrospective Study Using German Electronic Medical Records

. Hartmut Richter is an employee at IMS Health. Andreas Clemens is an employee at Novartis Pharma AG. Massoud Toussi is an employee at IMS Health. Wlodzimierz M. Kolaczynski, Matthew Hankins, Siew H. Ong ... , Hartmut Richter, Andreas Clemens, and Massoud Toussi declare that they have no other conflict of interest other than those listed above. Compliance with Ethics Guidelines. Data were de-identified and

Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD—a randomised controlled study

Domenighetti 0 Jean-Georges Frey 7 Alexander J. Turk 6 Andrea Azzola 5 Thomas Sigrist 4 Jean-William Fitting 9 Ulrich Schmidt 8 Thomas Geiser 2 Corinne Wild 11 Konstantinos Kostikas 12 Andreas Clemens 12 Martin ... and have given final approval of the version to be published. Competing interests Corinne Wild (CW) is a full-time employee of Novartis Pharma Schweiz AG. Andreas Clemens (AC) and Konstantinos

Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment

Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment Andreas Clemens,1 Mandy Fraessdorf,2 Jeffrey Friedman31Corporate Division ... well as collection and management of the data. Editorial assistance was provided by Elena Garonna from PAREXEL, with funding from Boehringer Ingelheim. Andreas Clemens, Mandy Fraessdorf, and Jeffrey

Twice- or Once-Daily Dosing of Novel Oral Anticoagulants for Stroke Prevention: A Fixed-Effects Meta-Analysis with Predefined Heterogeneity Quality Criteria

Background A number of novel oral anticoagulants (direct thrombin inhibitors or factor Xa inhibitors) are in clinical use for various indications. The dosing regimens differ between twice-daily and once-daily dosing for the prevention of stroke in patients with atrial fibrillation. With the availability of the results from four phase 3 studies (>70,000 patients), we explored...

Dabigatran Does Not Prolong the QT Interval with Supratherapeutic Exposure: a Thorough QT Study in Healthy Subjects

Background Dabigatran etexilate is a pro-drug of the oral reversible direct thrombin inhibitor dabigatran that interacts with the active site in the catalytic domain of the thrombin molecule. Objective To assess the electrophysiological effects of therapeutic and supratherapeutic doses of dabigatran etexilate in healthy subjects, a thorough QT study was performed. Methods In this...

Pharmacometric Characterization of Dabigatran Hemodialysis

Background Hemodialysis has been shown to be a useful method of decreasing dabigatran plasma levels in situations that require rapid elimination of this thrombin inhibitor. However, there is currently no clinical recommendation for the accelerated/optimized elimination of dabigatran via hemodialysis (e.g., flow rates, filter type, duration of dialysis). Objectives The primary...

Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile

Purpose Dabigatran etexilate is an oral, reversible, direct thrombin inhibitor licensed for the prevention of venous thromboembolism and stroke prevention in patients with atrial fibrillation. The aim of this study was to investigate whether, and to what extent, a switch from enoxparin to dabigatran etexilate affects the pharmacokinetic (PK) and pharmacodynamic (PD) parameters...